Inogen, Inc. Quarterly report [Sections 13 or 15(d)]

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2026

RSU activity for the nine months ended September 30, 2026 is summarized below:


										Weighted-
										average
										grant
				Performance						date fair
				and						value
	Time-based			time-based			Total			per share
Unvested RSUs as of December 31, 2025		1,494,415			1,177,278			2,671,693		$	8.58
Granted		933,319			698,250			1,631,569			6.65
Vested		(640,726	)		(70,607	)		(711,333	)		7.94
Forfeited/canceled		(251,280	)		(364,250	)		(615,530	)		8.39
Unvested RSUs as of September 30, 2026 (1)		1,535,728			1,440,671			2,976,399		$	7.69
Unvested and expected to vest RSUs outstanding as of September 30, 2026								2,016,476		$	7.65

(1) Outstanding RSUs are based on the maximum payout of the targeted number of shares.

Summary of Stock-based Compensation Expense

Stock-based compensation expense recognized for the three and nine months ended September 30, 2026 and 2025, was as follows:


	Three months ended				Nine months ended
	September 30,				September 30,
	2026		2025		2026		2025
Stock-based compensation expense by type of award:
RSUs	$	1,690	$	1,665	$	5,200	$	5,826
Employee stock purchase plan		68		70		217		297
Total stock-based compensation expense	$	1,758	$	1,735	$	5,417	$	6,123

For the three and nine months ended September 30, 2026 and 2025, respectively, stock-based compensation expense recognized under ASC 718, included in cost of revenue, research and development expense, sales and marketing expense, and general and administrative expense was as follows:


	Three months ended				Nine months ended
	September 30,				September 30,
	2026		2025		2026		2025
Cost of revenue	$	97	$	135	$	351	$	431
Research and development		127		72		397		236
Sales and marketing		147		171		246		548
General and administrative		1,387		1,357		4,423		4,908
Total stock-based compensation expense	$	1,758	$	1,735	$	5,417	$	6,123